News Posts List
AVEO Pharmaceuticals Completes Enrollment in Phase 2 Clinical Trial of AV-951
06/01/2008
"The positive Phase 1 data we presented last month at AACR, coupled with the high investigator and patient interest in this Phase 2 trial, suggests a significant market opportunity for a differentiated VEGF receptor inhibitor. Based on our promising, early data, we believe the unique triple VEGF receptor inhibition and tolerability positions AV-951 as a potential best-in-class anti-angiogenic agent."
Overall Survival Benefit With TORISEL Regardless of Nephrectomy
06/01/2008
The only renal cancer therapy proven to extend median overall survival compared with interferon-alpha in patients with advanced renal cell carcinoma (RCC).
NEW DATA FOR PAZOPANIB
06/01/2008
In patients with advanced renal cell cancer, there was an overall response rate of 35 percent.
Wyeth, Novartis see new benefits from cancer drugs
06/01/2008
Drug firms Wyeth and Novartis AG each reported new uses for their respective cancer drugs at a medical conference Saturday.
Cancer patients betrayed by NHS
06/01/2008
When Richard Eckley was diagnosed with kidney cancer, doctors offered him an unenviable choice.
Heat Shock Protein 90
06/01/2008
In renal cell and prostate cancer HIF-1α is degraded by Geldanamycin in both normoxia and hypoxia.
Management Of The Small Renal Mass - Observation Not Treatment
06/01/2008
Dr. Robert Uzzo argued for observation in many renal masses.
New Drug Helps Patients with Advanced Kidney Cancer Live Longer
05/31/2008
In the future, kidney cancer is likely to be managed as a chronic disease.
Zometa when added to hormone therapy, following surgery, significantly reduced the risk of cancer returning or death by 36%
05/31/2008
"This study is the first large-scale trial to demonstrate the significant antitumor benefit of zoledronic acid," said lead investigator Michael Gnant, M.D., of the Medical University of Vienna.
A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
05/31/2008
"In the INTORACT study, we hope to learn more about whether combining TORISEL with other agents in the first-line setting may further improve outcomes for patients with this devastating disease."